Oncology has developed into an increasingly strong pillar of growth for Johnson & Johnson and now the multiple myeloma blockbuster Darzalex (daratumumab) has surpassed the immunology power brand Stelara (ustekinumab) as the company’s top-selling drug. J&J reported first quarter sales on 16 April, with Darzalex continuing its strong double-digit rise while Stelara’s growth flattened.
Darzalex Surpasses Stelara As J&J’s Best-Selling Drug
Sales of Stelara are expected to begin tapering off later this year when the first biosimilars launch in mid-2024 in Europe and later in the US.
More from Earnings
More from Business
• By
The US FDA approved anti-CD19 antibody Uplizna, from Amgen’s $27.8bn purchase of Horizon in 2023, for IgG4-related disease – a larger market than its original NMOSD indication.
• By
BeiGene’s Phase III ociperlimab joins the list of failed TIGIT inhibitors, as candidates from Roche, Merck & Co. and others have failed late-stage studies.
• By
It might be the beginning of the end for the orphan drugs party but there is still sales growth enjoyment to be had for the sector, whose star performers are now looking increasingly like mainstream drugs.